Literature DB >> 30362111

Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities.

Sara N Salerno1, Gilbert J Burckart2, Shiew-Mei Huang2, Daniel Gonzalez1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30362111      PMCID： PMC6465091          DOI： 10.1002/cpt.1234

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  9 in total

1.  Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions.

Authors:  Farzaneh Salem; Trevor N Johnson; Zoe E Barter; J Steven Leeder; Amin Rostami-Hodjegan
Journal:  J Clin Pharmacol       Date:  2013-05-30       Impact factor: 3.126

2.  Do children have the same vulnerability to metabolic drug–drug interactions as adults? A critical analysis of the literature.

Authors:  Farzaneh Salem; Amin Rostami-Hodjegan; Trevor N Johnson
Journal:  J Clin Pharmacol       Date:  2013-05       Impact factor: 3.126

3.  An adaptive design to investigate the effect of ketoconazole on pharmacokinetics of GSK239512 in healthy male volunteers.

Authors:  Jianfeng Xu; Jan Hilpert; Kai Wu; Benjamin van Hecke; Gary Collins; Aarti Patel; Rajat Mohindra; Matt J B Davies; Yanmei Xu; Paul Thompson
Journal:  J Clin Pharmacol       Date:  2015-02-04       Impact factor: 3.126

4.  Potential drug-drug interactions in infant, child, and adolescent patients in children's hospitals.

Authors:  James Feinstein; Dingwei Dai; Wenjun Zhong; Jason Freedman; Chris Feudtner
Journal:  Pediatrics       Date:  2014-12-15       Impact factor: 7.124

5.  Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children's Hospitals.

Authors:  Dingwei Dai; James A Feinstein; Wynne Morrison; Athena F Zuppa; Chris Feudtner
Journal:  Pediatr Crit Care Med       Date:  2016-05       Impact factor: 3.624

6.  Predicting CD4 T-Cell Reconstitution Following Pediatric Hematopoietic Stem Cell Transplantation.

Authors:  R L Hoare; P Veys; N Klein; R Callard; J F Standing
Journal:  Clin Pharmacol Ther       Date:  2017-05-26       Impact factor: 6.875

7.  Dosing of Ceftriaxone and Metronidazole for Children With Severe Acute Malnutrition.

Authors:  Joseph F Standing; Martin O Ongas; Caroline Ogwang; Nancy Kagwanja; Sheila Murunga; Shalton Mwaringa; Rehema Ali; Neema Mturi; Moline Timbwa; Christine Manyasi; Laura Mwalekwa; Victor L Bandika; Bernhards Ogutu; Joseph Waichungo; Karin Kipper; James A Berkley
Journal:  Clin Pharmacol Ther       Date:  2018-04-19       Impact factor: 6.875

Review 8.  Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.

Authors:  Eva Germovsek; Charlotte I S Barker; Mike Sharland; Joseph F Standing
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 5.577

9.  Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children.

Authors:  Sophida Boonsathorn; Iek Cheng; Frank Kloprogge; Carlos Alonso; Charmion Lee; Bilyana Doncheva; John Booth; Robert Chiesa; Adam Irwin; Joseph F Standing
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 6.447
  9 in total
  9 in total

1.  Supportive care medications coinciding with chemotherapy among children with hematologic malignancy.

Authors:  Eman Biltaji; Elena Y Enioutina; Venkata Yellepeddi; Joseph E Rower; Catherine M T Sherwin; Robert M Ward; Richard S Lemons; Jonathan E Constance
Journal:  Leuk Lymphoma       Date:  2020-04-07

Review 2.  Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters.

Authors:  Kit Wun Kathy Cheung; Bianca D van Groen; Gilbert J Burckart; Lei Zhang; Saskia N de Wildt; Shiew-Mei Huang
Journal:  J Clin Pharmacol       Date:  2019-09       Impact factor: 3.126

3.  A whole of population retrospective observational study on the rates of polypharmacy in New Zealand 2014 to 2018 Polypharmacy in New Zealand: What is the current status?

Authors:  James Nind; Alesha Smith; Manjula Devananda; Benoit Auvray
Journal:  Health Sci Rep       Date:  2021-03-10

4.  Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations.

Authors:  Trevor N Johnson; Ben G Small; Karen Rowland Yeo
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-02-17

5.  Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants.

Authors:  Samit Ganguly; Andrea N Edginton; Jacqueline G Gerhart; Michael Cohen-Wolkowiez; Rachel G Greenberg; Daniel Gonzalez
Journal:  Clin Pharmacokinet       Date:  2021-06-22       Impact factor: 5.577

Review 6.  Pediatric Drug-Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations.

Authors:  Daniel Gonzalez; Jaydeep Sinha
Journal:  J Clin Pharmacol       Date:  2021-06       Impact factor: 2.860

7.  Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy.

Authors:  Yumi Cleary; Michael Gertz; Paul Grimsey; Andreas Günther; Katja Heinig; Kayode Ogungbenro; Leon Aarons; Aleksandra Galetin; Heidemarie Kletzl
Journal:  Clin Pharmacol Ther       Date:  2021-09-01       Impact factor: 6.903

8.  Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  Front Pharmacol       Date:  2020-01-30       Impact factor: 5.810

9.  Evaluation of potential drug-drug interactions in a pediatric population.

Authors:  Berna Terzioğlu Bebitoğlu; Elif Oğuz; Çağatay Nuhoğlu; Ayşe Ela Kurtdan Dalkılıç; Pelin Çirtlik; Fatime Temel; Ajla Hodzic
Journal:  Turk Pediatri Ars       Date:  2020-03-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.